We selected two target proteins (CCL2 and STAT1) with the strongest regulatory interaction with NASH and hepatitis C (Supplementary Table S3) for molecular docking analysis to predict their potential therapeutic effects. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.